Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

Area of Science:

• Neuro-oncology
• Immunotherapy
• Cancer Biology

Background:

• Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown promise in various cancers, but not glioblastoma multiforme (GBM).
• Previous research indicated that temozolomide (TMZ) treatment reduces PD-L1 expression in GBM patients.
• This study investigates the relationship between TMZ therapy and PD-L1, a key immune checkpoint target.

Purpose of the Study:

• To explore the impact of temozolomide (TMZ) on PD-L1 expression in glioblastoma multiforme (GBM).
• To understand the underlying mechanisms connecting TMZ treatment and PD-L1 regulation.
• To assess the implications for PD-1/PD-L1 inhibitor efficacy in GBM.

Main Methods:

• Analysis of RNA-sequencing data from de-novo and recurrent GBM using AutoPipe algorithm.
• Validation in GBM cell models and patient specimens.
• Quantitative real-time PCR and western blot to assess PD-L1 and JAK/STAT pathway activation.

Main Results:

• Recurrent GBM tumors showed a significant downregulation of the JAK/STAT pathway and immune response.
• In cell models, IFNγ treatment upregulated PD-L1, but subsequent TMZ treatment reduced PD-L1 expression and JAK/STAT pathway activation.
• These findings were consistent in both de-novo and recurrent GBM patient specimens.

Conclusions:

• TMZ therapy demonstrably downregulates PD-L1 in primary GBM cells.
• This downregulation aligns with reduced PD-L1 levels observed in recurrent GBM.
• Diminished PD-L1 may compromise the effectiveness of PD-1/PD-L1 inhibitors like nivolumab in GBM treatment.